Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance

Prostate

Volumn 72, Issue 10, 2012, Pages 1117-1123

  O'Malley, Katherine J ^a   Langmann, Gabrielle ^a   Ai, Junkui ^a   Ramos Garcia, Raquel ^a   Vessella, Robert L ^b   Wang, Zhou ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

androgen receptor; castration resistance; HSP90; LuCaP35

Indexed keywords

ANDROGEN RECEPTOR; TANESPIMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RELAPSE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BENZOQUINONES; CELL LINE, TUMOR; DISEASE PROGRESSION; HSP90 HEAT-SHOCK PROTEINS; LACTAMS, MACROCYCLIC; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861574636     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22458     Document Type: Article

References (29)

1. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED,. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351 (15): 1513-1520.
2. Kantoff PWHC, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF,. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med 2010; (363): 411-422.
3. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL,. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10 (1): 33-39.
4. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ,. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002; 62 (4): 1008-1013.
5. Mellado BCJ, Ribal MJ, Visa L, Gascõn P,. Molecular biology of androgen-independent prostate cancer: The role of the androgen receptor pathway. Clin Transl Oncol 2009; 11 (1): 5-10.
6. Zhou Z, Wong C, Sar M, Wilson E,. The androgen receptor: An overview. [Review]. Recent Prog Horm Res 1994; 49: 249-274.
7. Georget V, Lobaccaro JM, Terouanne B, Mangeat P, Nicolas JC, Sultan C,. Trafficking of the androgen receptor in living cells with fused green fluorescent protein-androgen receptor. Mol Cell Endocrinol 1997; 129 (1): 17-26.
8. Simental JA, Sar M, Lane MV, French FS, Wilson EM,. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 1991; 266 (1): 510-518.
9. Roy AK, Tyagi RK, Song CS, Lavrovsky Y, Ahn SC, Oh TS, Chatterjee B,. Androgen receptor: Structural domains and functional dynamics after ligand-receptor interaction. Ann N Y Acad Sci 2001; 949: 44-57.
10. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM,. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001; 61 (7): 2892-2898.
11. Zhang L, Johnson M, Le KH, Sato M, Ilagan R, Iyer M, Gambhir SS, Wu L, Carey M,. Interrogating androgen receptor function in recurrent prostate cancer. Cancer Res 2003; 63 (15): 4552-4560.
12. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N,. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 2010; 70 (20): 7992-8002.
13. DeFranco DB, Ramakrishnan C, Tang Y,. Molecular chaperones and subcellular trafficking of steroid receptors. J Steroid Biochem Mol Biol 1998; 65 (1-6): 51-58.
14. Pratt WB, Toft DO,. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 1997; 18 (3): 306-360.
15. Georget V, Terouanne B, Nicolas JC, Sultan C,. Mechanism of antiandrogen action: Key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry 2002; 41 (39): 11824-11831.
16. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N,. 17-Allylamino-17- demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002; 8 (5): 986-993.
17. Helmbrecht K, Zeise E, Rensing L,. Chaperones in cell cycle regulation and mitogenic signal transduction: A review. Cell Prolif 2000; 33 (6): 341-365.
18. Münster PNSM, Moasser MM, Rosen N,. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res 2001; 61 (7): 2945-2952.
19. Webb CPHC, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, Vande Woude GF,. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 2000; 60 (2): 342-349.
20. Lamoureux F, Thomas C, Yin MJ, Kuruma H, Fazli L, Gleave ME, Zoubeidi A,. A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin Cancer Res 2011; 17 (8): 2301-2313.
21. Saporita AJ, Ai J, Wang Z,. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate 2007; 67 (5): 509-520.
22. Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, Vessella RL,. LuCaP 35: A new model of prostate cancer progression to androgen independence. Prostate 2003; 55 (4): 239-246.
23. Euhus DMHC, LaRegina MC, Johnson FE,. Tumor measurement in the nude mouse. J Surg Oncol 1986; 31 (4): 229-234.
24. Tomayko MMRC,. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989; 24: 148-154.
25. Goetz MPTD, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S, Adjei A, Croghan G, Erlichman C,. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005; 23 (6): 1078-1087.
26. Heath EIHD, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, Pili R, Carducci MA, Erlichman C, Liu G,. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2008; 14 (23): 7940-7946.
27. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP,. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005; 18 (5): 601-607.
28. Ai J, Wang Y, Dar JA, Liu J, Liu L, Nelson JB, Wang Z,. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer. Mol Endocrinol 2009; 23 (12): 1963-1972.
29. De Leon JT, Iwai A, Feau C, Garcia Y, Balsiger HA, Storer CL, Suro RM, Garza KM, Lee S, Kim YS, Chen Y, Ning YM, Riggs DL, Fletterick RJ, Guy RK, Trepel JB, Neckers LM, Cox MB,. Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proc Natl Acad Sci USA 2011; 108 (29): 11878-11883.